Braun Stacey Associates Inc. Sells 654 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Braun Stacey Associates Inc. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,492 shares of the biopharmaceutical company's stock after selling 654 shares during the period. Braun Stacey Associates Inc.'s holdings in Regeneron Pharmaceuticals were worth $15,309,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Mizuho Securities USA LLC increased its holdings in shares of Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock valued at $62,382,000 after purchasing an additional 51,162 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after purchasing an additional 2,828 shares during the period. Simplify Asset Management Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company's stock valued at $10,082,000 after purchasing an additional 3,231 shares during the period. Golden State Equity Partners increased its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock valued at $967,000 after purchasing an additional 1,272 shares during the period. Finally, ABC Arbitrage SA acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $1,510,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 0.6 %

Regeneron Pharmaceuticals stock traded up $4.31 during mid-day trading on Friday, hitting $700.33. The company's stock had a trading volume of 727,332 shares, compared to its average volume of 923,518. The firm's 50 day moving average is $699.40 and its 200 day moving average is $883.75. The company has a market cap of $76.56 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 2.30 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the business earned $11.86 EPS. The business's revenue for the quarter was up 10.3% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on REGN. Citigroup decreased their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research note on Tuesday, February 4th. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an "outperform" rating and a $1,150.00 target price for the company. JPMorgan Chase & Co. decreased their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. Finally, Evercore ISI decreased their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.